In the American pharmaceutical company MERCK presented the test results of the drug Melubiraira from COVID-19 in the form of tablets, the New Atlas reports.
It is noted that, according to the results of intermediate tests in the company, the company was previously reported that the reception of the drug reduces the risk of developing heavy symptoms of coronavirus and fatal outcome by 50%. However, after receiving the final data, it turned out that the drug is only 30% effective.
In this regard, in the management of sanitary supervision of the quality of food and drugs, the United States voiced 2 questions: whether the meal of the mooring of Coronavirus mutations contributes and whether they need close attention. It is also unclear how safe the drug is in relation to pregnant women.